AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05240677 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Upper GIT endoscopy
Description: Upper gastrointestinal endoscpy for all participants and gastric biopsy for histopathological examination for suspicious lesions
Study NCT05240677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper GIT endoscopy
Description: Upper gastrointestinal endoscpy for all participants and gastric biopsy for histopathological examination for suspicious lesions
Study NCT04875065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage coaching
Description: Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands.
Study NCT05432713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-168 tablet
Description: Lp-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
Study NCT05432713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LP-168 Placebo tablet
Description: LP-168 placebo tablets contain excipients for LP-168 tablets, but do not contain the active ingredients of the drug, and are used for comparison in clinical trials with the same usage and dosage as LP-168 tablets
Study NCT06147999 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Biophotonizer - a Biophoton Generator
Description: A biophotonizer is a device producing strong biophoton field. These biophotons help the human body to gain self-healing capacity to heal many disorders, including brain disorders.
Study NCT06147999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biophotonizer - a Biophoton Generator
Description: A biophotonizer is a device producing strong biophoton field. These biophotons help the human body to gain self-healing capacity to heal many disorders, including brain disorders.
Study NCT06248333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN-DBS ON
Description: Stimulation ON
Study NCT06248333 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: STN-DBS OFF
Description: Stimulation OFF
Study NCT04871425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV ketamine
Study NCT04871425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: IV fentanyl
Study NCT05167435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Experimental
Description: Myofascial release is a gentle sustained pressure that elongates fascial adhesions so that tissue can return to proper realignment.
Study NCT05167435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posterior-Anterior Glide
Description: Posterior-anterior mobilization is a standard assessment and treatment technique for most clinicians. It is a mobilization technique that involves passive oscillatory movements applied to a vertebral segment in a posteroanterior direction (Back to front).
Study NCT05195567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucometer Test
Description: measurement of the blood glucose concentration using the blood glucose monitor for personal use
Study NCT05195567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement, laboratory reference device
Description: measurement of the blood glucose concentration using a laboratory reference device
Study NCT05068258 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphovenous bypass, including lymphaticovenular anastomosis/implantation
Description: Lymphovenous bypass (LVB) is a supermicrosurgical technique by diverting lymphatic drainage into venous system. Simultaneously, we performed LVB at ipsilateral foot dorsum and debride the VLUs and resurface the wound primarily or by skin graft depending on defect size.
Study NCT03222726 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise group
Description: less than 6000 steps/day or 40,000 steps/week
Study NCT04167813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg or matched placebo tablets
Description: Participants will take one tablet daily in weeks 1 and 2, two tablets daily in weeks 3 and 4 and 3 tablets daily in weeks 5 and 6.~Dose escalation will be guided by tolerability, through telephone safety monitoring prior to each dose increase
Study NCT05598671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCNL without reverse insertion of a ureteral catheter
Description: The ureteral catheter was not retrograde inserted during PCNL
Study NCT04167813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron 8mg or matched placebo tablets
Description: Participants will take one tablet daily in weeks 1 and 2, two tablets daily in weeks 3 and 4 and 3 tablets daily in weeks 5 and 6.~Dose escalation will be guided by tolerability, through telephone safety monitoring prior to each dose increase
Study NCT05529693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Bif-038 arm, high dose
Description: Active trial product with minimum 10 billion CFU daily dose
Study NCT05529693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Bif-038 arm, low dose
Description: Active trial product with minimum 1 billion CFU daily dose
Study NCT05529693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo arm
Description: Similar product to trial product but without Bif-038
Study NCT04242251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPARKLE Model of care
Description: Patients will receive the SPARKLE model of care in addition to usual oncologist-led care. The SPARKLE model will be led by a palliative medicine doctor and administered by nurses and staff without specific nursing or medical training. It utilizes a stepped care approach where all patients will initially have low-intensity model focused on weekly symptom monitoring through a patient-reported questionnaire. If any problems are identified, then patients step up to a higher-intensity care model where a nurse will conduct a phone assessment of the symptom problems. If the presence of symptoms is confirmed, patients step up again to an even higher-intensity care model where treatment of symptoms will be initiated by the SPARKLE nurse, depending on the severity of the problems. If the symptoms are not fully resolved, the patients will then step up to the highest-intensity care model which is an existing palliative care service- either palliative care outpatient clinic or home hospice.
Study NCT05478239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ArtemiCoffee
Description: 3 cups of Artemisia annua (Aa) coffee per day (1350mg) for 24 weeks.
Study NCT05668910 — intervention group
Intervention type: GENETIC
Intervention: whole genomic methylation and fragmentation profile analysis of cfDNA
Description: The assay for gastric cancer early detection will be built based on low-depth methylone sequencing followed with a multi-dimensional model construction with analysing several features such as methylation, fragmentation, and chromosomal copy number alternation.
Study NCT02859714 — intervention group
Intervention type: OTHER
Intervention: screening data
Study NCT05851053 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: During echocardiography, the following parameters will be assessed:~* Dimensions~* Left ventricle function~* Right ventricle function~* Valves: Aorta valve and pulmonic valve~* Other findings such as: frequency, rhythm, quality
Study NCT04540887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field (PEMF) Therapy
Description: PEMF therapy will be self-administered by all trial participants using the B. Body, B. Pad, and Control Unit. Participants will administer this therapy twice a day (morning and evening) for 8-minute sessions over a four week period.
Study NCT04831151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin
Description: Yasmin: 0,03 mg ethinylestradiol + 3 mg drospirenone
Study NCT04831151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diane-35
Description: Diane 35: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate
Study NCT05586139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiome-directed food - MAM
Description: Each MAM child will be supplemented with MDF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
Study NCT05874024 — intervention group
Intervention type: PROCEDURE
Intervention: induction of labour with double balloon catheter placement for 6 hours
Description: catheter placement for 6 hours beginning in the morning at around 8 a.m.
Study NCT05874024 — intervention group
Intervention type: PROCEDURE
Intervention: induction of labour with double balloon catheter placement for 12 hours
Description: catheter placement for 12 hours in the evening at around 8 p.m.
Study NCT05724745 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 1. Standard spirometry
Description: Spirometry is performed in two positions (sitting and supine) and three types of breathing (spontaneous, forced and slow).
Study NCT05724745 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 2. 3D dynamic lung MRI at UTE in prone and supine positions
Description: Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine before a reversibility test with salbutamol.
Study NCT05724745 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 3. Reversibility test with salbutamol
Description: Reversibility test with salbutamol administered using a pressurized metered dose bottle and an inhalation chamber at a dosage of 100 μg, 4 times (i.e., 400 μg in total).
Study NCT05724745 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 4. 3D dynamic lung MRI at UTE in supine and prone position
Description: Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine after the bronchodilatator's administration.
Study NCT05586139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready-to-use supplementary food (RUSF)
Description: Each MAM child will be supplemented with RUSF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
Study NCT05849805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracalvaria bone marrow injection
Description: Intracalvaria bone marrow injection Y-3 (dose was given at 32 ug/kg), continuous medication for 3 days
Study NCT05849805 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: standard treatment and management according to related guidelines
Study NCT05849805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: standard treatment and management according to related guidelines
Study NCT04802434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengthening Skills Program
Description: The Strengthening Skills Program is a new, multi-component intervention. It includes three components: (1) Forming habits to compensate for the difficulties many adults with ASD have with thinking flexibly, planning, and time management. It will emphasize habit-forming behaviors to compensate for weaknesses in functional skills by training on practical techniques; (2) Content from the PEERS Social Skills program to target social challenges, and (3) strategies derived from Mindfulness Based Stress Reduction to target emotion regulation.
Study NCT04802434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PEERS Social Skills Program
Description: PEERS® is a well-established social communication training program, initially developed for adolescents, and more recently extended to young adults with ASD. Program content will be adapted slightly so as to be appropriate for older adults.
Study NCT04802434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS Social Skills Program
Description: PEERS® is a well-established social communication training program, initially developed for adolescents, and more recently extended to young adults with ASD. Program content will be adapted slightly so as to be appropriate for older adults.
Study NCT05586139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiome-directed food (MDF) - SAM
Description: Each SAM child will be supplemented with MDF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
Study NCT05586139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready-to-use therapeutic food (RUTF)
Description: Each SAM child will be supplemented with RUTF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
Study NCT04596293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-401-1S or Placebo
Description: Administered by 200mg capsules of BBT-401-1S or placebo
Study NCT04596293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BBT-401-1S or Placebo
Description: Administered by 200mg capsules of BBT-401-1S or placebo
Study NCT05903352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop antibiotic
Description: Stop the antibiotic treatment on day S (stability criteria reached for 24 h or within 48 hours after the start of antibiotic treatment).
Study NCT05092672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will engage in moderate-intensity (40-59% HRR) exercise for 30 min
Study NCT01952886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Study NCT01952886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Study NCT05051579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally
Study NCT05051579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT05301517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SEPO®
Description: SEPO® will be administered per dose and schedule specified in the arm description.
Study NCT05301517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arm description.
Study NCT06420089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senza5 CART5
Description: The Senza5 CART5 drug product consists of a dual population of engineered autologous T cells: CD5 knockout (KO)cells and CD5KO-CART5 cells
Study NCT05915299 — intervention group
Intervention type: DEVICE
Intervention: OCS Heart
Description: The TransMedics® Organ Care System (OCS) Heart System is an FDA approved portable extracorporeal heart perfusion and monitoring system.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation.
Study NCT05245201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Two control clinics will be selected based on a set of matching criteria, e.g., urbanity and the sex, race, and age distributions of the patient population. Control clinics will not participate in study activities.
Study NCT05245201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical decision support for PrEP
Description: Healthcare providers at 2 intervention clinics (total of approximately 60 providers anticipated) will be prompted by an EHR-based tool to discuss PrEP with patients whose demographics and clinical history indicate increased predicted HIV risk. Providers will be offered clinical decision support tools to guide sexual health discussions and support PrEP prescribing.
Study NCT05349630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate 325mg
Description: Participants will take one tab of ferrous sulfate 325 mg (equivalent to 65 mg elemental iron) daily for 30 days.
Study NCT05349630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous sulfate 325mg
Description: Participants will take one tab of ferrous sulfate 325 mg (equivalent to 65 mg elemental iron) daily for 30 days.
Study NCT05638425 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy combined with PD-1 inhibitors
Description: Radiotherapy should be carried out within 4 weeks after the first dose of PD-1 inhibitor; the radiotherapy method should be determined according to the patient's condition; PD-1 inhibitor and chemotherapy should refer to the actual product instructions
Study NCT06693089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIT-ED
Description: The aim is to develop healthier strategies for managing negative thoughts and feelings linked to Eating Disorder (ED) and engage patients in social interactions that fulfill their relational needs. Participants will learn that perfectionism and the need for control in ED are coping strategies shaped by interpersonal patterns with significant others, where low self-esteem and emotional dysregulation play key roles. Metacognitive Intepersonal Therapy (MIT) aims to improve individuals' ability to understand their own emotions and thoughts, recognizing maladaptive, rigid, and biased schemas about self and others. This awareness helps them form a richer understanding of others' minds and use this knowledge to respond more adaptively to social challenges. MIT also helps individuals reflect on how these schemas trigger ED behaviors and develop better coping strategies for interpersonal stressors.
Study NCT05568732 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage procedure will be done with VCMX
Description: Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with VCMX using minimally invasive access technique.
Study NCT05568732 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root coverage procedure will be done with CTG
Description: Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.
Study NCT05781100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Use during Feeding Conditions
Description: At 1 month and 4 months, mother-infant dyads will be observed during 3 different feeding conditions counterbalanced across 3 days, with a 1-day wash-out period between conditions: TV Use condition: mothers will be asked to watch a 22-minute long TV show on a large tablet while they feed their infants. Mothers will choose from four preselected episodes of popular sitcoms. Mobile Device Use condition: mothers will be asked to use their mobile device in a way they find relaxing and pleasurable. Control condition: mothers will be asked to feed their infant in a room free of all potential technological distractions. During all conditions, mothers will feed their infants their typical milk (breast milk or formula) from their typical mode (breast or bottle).
Study NCT06106620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink consisting of 12 oz of flavor-matched water.
Study NCT06106620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Safety Shot
Description: Safety Shot consisting of a 12 oz drink containing vitamins, mineral, and botanical extracts.
Study NCT05471830 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: No drug will be provided to participants. Patients follow routine clinical practice/administration.
Study NCT05385432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Anti thymocyte globulin (rATG)
Description: The infusion of rTAG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained.
Study NCT06472492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adjuvant yoga intervention
Description: The yoga will include following asanas under the supervision of a yoga therapist. This will include Griva Shithilikarana, Skandha Sanchalana , Kati Sanchalana, Jaanu Sanchalana, Pada Sanchalana, Tadasana, Kati Sakti Vikasaka, Konasana,Marjari Asana, Vakrasana, Pascimottanasana, Matsyasana, Bhujangasana, Ardha Shalabhasana, Viparitakarani, Pavanamuktasana, Setubhandasana, Shavasana, Kapalabhati, Surya-anuloma pranayama, Chandraanuloma pranayama, Bhastrika, Bhramari Pranayama, Nadanusandhana.
Study NCT05802589 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Erector Spinae Plane Block
Description: Erector spinae plane block was applied with a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) using in-plane technique using a convex USG transducer from the 4th lumbar vertebral level.
Study NCT05802589 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Group Block
Description: Pericapsular nerve group block was performed using a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) and a convex USG transducer using an in-plane technique under the iliopsoas muscle in the plane between the iliopsoas tendon and the periosteum and between the anterior inferior iliac spine and the iliopubic eminence.